In the control arm, 75% of patients received four cycles of chemotherapy with 159 of 238 (67%) patients with non-squamous tumor histology receiving pemetrexed maintenance. The median (range) number of doses was 9.0 (1-36) for nivolumab and 4.0 (1-18) for ipilimumab. The majority (93%) of patients received two cycles of chemotherapy and 13% completed the maximum 2 years of immunotherapy treatment ( Supplementary Figure S2, available at ). In the experimental arm, consistent with the duration of therapy per protocol, no patients remained on study treatment. Minimum follow-up for all other analyses was 23.3 months. Statistical analysesĪt the database lock (DBL 18 February 2021), minimum follow-up for OS was 24.4 months (median, 30.7 months). Further details on endpoints and assessments can be found in the Supplementary Methods, available at. Post hoc analyses included assessment of onset of grade 1/2 or grade 3/4 TRAEs (reported between first dose and 30 days after last dose of study treatment) by treatment cycle in each arm, assessment of efficacy in patients who discontinued all components of treatment due to TRAEs, and assessment of treatment-free interval (time from last dose of study treatment to start of subsequent systemic treatment or death) in the experimental arm. Endocrine adverse events were considered IMAEs regardless of immune-modulating medication use, since endocrine drug reactions are often managed without immune-modulating medication.
Immune-mediated adverse events (IMAEs) were defined as specific events (or groups of preferred terms describing specific events) that included pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine (adrenal insufficiency, hypothyroidism/thyroiditis, hypothyroidism, thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-mediated events by the investigator, regardless of causality, that occurred within 100 days of the last dose, with no clear alternate etiology based on investigator assessment, or with an immune-mediated component, that were treated with immune-modulating medication. Patients who were alive and without progression after the next line of therapy were censored at the last known alive date. PFS2 was a pre-specified exploratory endpoint and was defined as time from randomization to objectively documented progression after the next line of therapy, per investigator assessment, or to death from any cause, whichever occurred first. Īt 2-year minimum follow-up, exploratory analyses included updated efficacy and safety outcomes. Histology-based chemotherapy regimens used in both treatment arms are summarized in the Supplementary Methods, available at.
Patients were randomized 1 : 1 to nivolumab (360 mg every 3 weeks) plus ipilimumab (1 mg/kg every 6 weeks) combined with histology-based platinum-doublet chemotherapy (every 3 weeks for two cycles) or chemotherapy alone (every 3 weeks for four cycles) ( Supplementary Figure S1, available at ). Patients were stratified by tumor histology (squamous versus non-squamous), sex (male versus female), and PD-L1 expression (<1% versus ≥1%) patients who could not be assessed for tumor PD-L1 expression (maximum of 10% of all randomized patients) were stratified with the PD-L1 expression <1% population however, these patients were only included in analyses of all randomized patients and were excluded from PD-L1 expression <1% subgroup analyses.
Here's how to convert a Keynote presentation to PowerPoint.CheckMate 9LA was an international, randomized, open-label phase III study. The file type at the end of your upload name should read ".pptx." It will read ".key" if it's still a Keynote file.
It saves Windows users the trouble of using a third-party app to open their Apple file.Īfter you've converted the Keynote file to a PowerPoint file, you can check that your presentation saved correctly when you attach it to an email. When sharing documents with non-Apple users and in general, converting your files to the more universal Microsoft applications helps to ensure that the recipient can open the file you send.Ĭonverting your Keynote files to the corresponding Microsoft PowerPoint format takes just a few clicks.
These include Pages (a word processor similar to Microsoft Word), Numbers (a spreadsheet application similar to Microsoft Excel), and Keynote (a presentation application similar to PowerPoint).
Mac users have access to several applications with similar functions to corresponding Microsoft programs.